Entrada Therapeutics Inc (TRDA)
Healthcare
Biotechnology
—
6.80 $
+0.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Entrada Therapeutics Inc (TRDA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -129 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -11 | -26 | -51 | -94 | 140 | -42 | -129 | |
| 0.1 | 0.3 | 1.1 | 1.9 | 2.8 | 3.8 | 4.1 | |
| 0.3 | 0.3 | 2.5 | 9.9 | 13 | 18 | 20 | |
| -6.0 | 0.3 | 2.6 | 10 | – | – | – | |
| 0.2 | 0.3 | -3.4 | -11 | 136 | -119 | -4.8 | |
| 0.6 | 2.3 | 4.6 | 2.9 | 5.6 | 3.2 | 1.0 | |
| -0.6 | -2.3 | -4.6 | -149 | -138 | -28 | 117 | |
| – | – | 191 | 0.3 | 0.4 | 0.6 | 0.5 | |
| 0.0 | 50 | 307 | 0.5 | 21 | 103 | 0.9 | |
| 17 | 22 | 252 | -246 | 22 | 34 | -11 | |
| -11 | -28 | -55 | -97 | 134 | -45 | -130 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.